Short Interest in PharmaCyte Biotech, Inc. (NASDAQ:PMCB) Grows By 82.3%

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 26,800 shares, a growth of 82.3% from the February 28th total of 14,700 shares. Based on an average daily volume of 17,700 shares, the short-interest ratio is currently 1.5 days. Approximately 0.4% of the company’s shares are sold short.

PharmaCyte Biotech Trading Down 4.3 %

Shares of NASDAQ:PMCB traded down $0.06 on Friday, reaching $1.32. 11,380 shares of the company traded hands, compared to its average volume of 21,782. The stock has a market capitalization of $9.06 million, a P/E ratio of 2.49 and a beta of -0.25. The business’s 50-day simple moving average is $1.63 and its 200 day simple moving average is $1.69. PharmaCyte Biotech has a 52 week low of $1.29 and a 52 week high of $2.55.

PharmaCyte Biotech (NASDAQ:PMCB) last posted its quarterly earnings results on Monday, March 17th. The company reported ($0.10) earnings per share (EPS) for the quarter.

PharmaCyte Biotech Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.